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Abstract
Background. Antiphospholipid syndrome (APS) is an autoimmune disease associated with venous or arterial 
thrombosis and pregnancy loss, but also infrequently with non-criteria APS manifestations such as thrombocy-
topenia, livedo reticularis and heart valve disease. The occurrence of antiphospholipid antibodies is necessary to 
diagnose APS and includes the presence of lupus anticoagulant and anticardiolipin as well as anti-β2-glycoprotein 
I antibodies, both in IgM and/or IgG isotype.
Objectives. The aim of this study was to evaluate the associations between antiphospholipid antibodies includ-
ing IgA isotype and IgG anti-domain I of β2-glycoprotein I (β-2GPI-D1) and non-criteria-related manifestations 
of APS.
Material and Methods. Thirty-three consecutive APS patients (26 women, 7 men, aged 44.1 ± 15 years), including 
23 (69.7%) subjects with primary APS, were enrolled. Together with standard antiphospholipid antibodies, IgA 
anticardiolipin, IgA anti-β2-glycoprotein I and IgG anti-β-2GPI-D1 antibodies in serum samples were evaluated 
by chemiluminescence using the QUANTA Flash® System.
Results. Livedo reticularis (n = 8, 24.2%) was associated with increased levels of IgG anti-β-2GPI-D1 (p = 0.005), 
IgA anticardiolipin (p = 0.001) and IgA anti-β2-glycoprotein I (p = 0.002) antibodies. Heart valve disease (n = 9, 
27.3%) was observed in patients with higher IgG anti-β-2GPI-D1 (p = 0.01). The associations of HVD with increased 
levels of IgA aCL and IgA anti-β-2GPI tended to be significant (p = 0.07). None of antiphospholipid antibodies 
showed association with thrombocytopenia (n = 6, 18.2%).
Conclusions. Our study suggests that increased IgA antiphospholipid antibodies and IgG anti-β-2GPI-D1 anti-
bodies may be involved in the development of livedo reticularis and heart valve disease in APS patients (Adv Clin 
Exp Med 2014, 23, 5, 729–733).
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The antiphospholipid syndrome (APS) is an 
autoimmune disease associated with increased risk 
of venous thromboembolism or ischemic stroke 
and/or pregnancy loss [1, 2]. Other non-crite-
ria APS manifestations include livedo reticularis 
(LR), thrombocytopenia and heart valve disease 
(HVD) [3]. These manifestations can be observed 
in 20–30% of the APS patients [4, 5].
Laboratory criteria of APS include the pres-
ence of lupus anticoagulant (LA) in plasma, the 
occurrence of anticardiolipin (aCL) antibodies of 
IgG and/or IgM isotype in serum or plasma in me-
dium or high titer as well as anti-beta-2-glycopro-
tein (β-2GPI) antibodies of IgG and/or IgM isotype 
in serum or plasma in titer over the 99th percen-
tile, all detected on two or more occasions at least 
12 weeks apart [6, 7].
IgA aCL and anti-β-2GPI antibodies have been 
reported in up to 70% of patients with systemic lu-
pus erythematosus (SLE) and in those with prima-
ry APS [8]. The role of these antibodies in APS is, 
however, unclear. Lagos et al. [3] found that LR, 
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HVD, thrombocytopenia, and epilepsy are more 
common among subjects with increased IgA anti-
β-2GPI antibodies. They also reported associations 
between increased IgA aCL antibodies and both 
LR and epilepsy [3]. A similar association was ob-
served in SLE patients [9] especially in those with 
thrombocytopenia [10].
Another antiphospholipid antibody, IgG an-
ti-domain I of β2-glycoprotein I (β-2GPI-D1), was 
reported in APS patients with no associations with 
any non-criteria APS manifestations [11–13].
We sought to investigate the associations of 
non-criteria APS manifestations with IgA isotype 
and IgG β-2GPI-D1 antibodies.
Material and Methods
Thirty-three APS patients, including 26 wom-
en, below 65 years of age were recruited between 
February 2012 to August 2013 in the Center for 
Coagulation Disorders in Krakow, Poland. The 
patients fulfilled the current criteria for APS [7]. 
Once the diagnosis of primary APS was estab-
lished, coagulation treatment was recommend-
ed to all patients. The exclusion criteria were the 
following: acute infections, severe inflammatory 
disorders other than autoimmune disorders (e.g. 
nephrotic syndrome, inflammatory bowel dis-
ease), overt malignancy, use of oral contraceptives 
or hormone replacement therapy, atrial fibrilla-
tion, heart failure, diabetes mellitus, serum creat-
inine > 120 µmol/L. Deep vein thrombosis (DVT) 
was diagnosed with positive finding of color du-
plex sonography, whereas the diagnosis of pulmo-
nary embolism (PE) was based on representative 
symptoms and positive results of high-resolution 
spiral computed tomography. Ischemic stroke was 
defined based on the WHO criteria. HVD was di-
agnosed based on echocardiographic evidence of 
thickening cardiac mitral and/or aortic valves. Pa-
tients with LR had permanent self-reported live-
do on the trunks and extremities confirmed by 
the investigator (A.U.) at room temperature on 
2 separate occasions. Thrombocytopenic patients 
had less than 100,000 platelets per 1 mm3 if oth-
er known causes were excluded. All patients gave 
written informed consent.
All patients were screened for thrombophil-
ia, including the factor V Leiden, prothrombin 
G20210A, antithrombin, protein C, free protein S. 
Inherited thrombophilia was defined as the pres-
ence of either of the two mutations or a deficien-
cy of one of the three coagulation inhibitors. An 
evaluation of LA was performed using a clot-based 
assay according to the current criteria for LA de-
tection [14]. A ratio more than 1.2 was considered 
positive for LA. The levels of IgG and IgM aCL 
and anti-β-2GPI antibodies were determined by 
enzyme-linked immunosorbent immunoassays 
(QUANTA Lite™ ELISAs, INOVA Diagnostic, Inc, 
San Diego, CA). Reference ranges for IgG were up 
to 13.1 GPL and 15.7 SGU, respectively, and for 
IgM up to 17.3 MPL and 14 SMU, respectively. All 
positive cases were assessed after 12–16 weeks.
IgA antibodies isotypes of aCL, anti-β-2GPI 
Table 1. Characteristics of APS patients
Variable Total (n = 33)
Age – years 44.1 ± 15.0
Male  7 (21.1)
SAPS 10 (30.3)
DVT 17 (51.5) 
Recurrent pregnancy loss  8 (24.2)
PE  2 (6.1)
Stroke  8 (24.2)
CVST  6 (18.2)
Livedo reticularis  8 (24.2)
Heart valve disease  9 (27.3)
Thrombocytopenia  6 (18.2)
Inherited thrombophilia 10 (30.3)
ASA  3 (9.1)
LMWH  2 (6.1)
VKA  4 (12.1)
LA positive 10 (30.3)
IgG anti-β-2GPI (> 15.7 SGU) 11 (33.3)
IgM anti-β-2GPI (> 14 SMU) 16 (48.5)
IgG aCL (> 13.1 GPL) 16 (48.5)
IgM aCL (> 17.3 MPL) 15 (45.5)
IgA anti-β-2GPI (> 20 CU)  6 (18.2)
IgA aCL (> 20 CU)  6 (18.2)
anti-β-2GPI-D1 (> 19.9 CU) 10 (30.3)
Data are given as mean ± standard deviation or number 
(percentage). ASA – acetylsalicylic acid; aCL – anticardio-
lipin; β-2GPI – beta-2-glycoprotein I;  
β-2GPI-D1 – domain I of beta-2-glycoprotein I; 
CU – chemiluminescent unit; CVST – cerebral venous 
sinus thrombosis; DVT – deep venous thrombosis; 
GPL – IgG phospholipid unit; LA – lupus anticoagulant; 
LMWH – low molecular weight heparin; MPL – IgM 
phospholipid unit; PE – pulmonary embolism; 
SAPS – secondary APS; SMU – standard IgM units; 
SGU – standard IgG units, VKA – vitamin K antagonist.
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and IgG anti-β-2GPI-D1 in serum samples were 
determined by chemiluminescence on the BIO-
FLASH® instrument (INOVA Diagnostic, Inc, San 
Diego, CA). Reference ranges for aCL, anti-β-2GPI 
were up to 20.0 CU and for anti-β-2GPI-D1 was 
up to 19.9 CU.
Depending on the distribution, as assessed by 
Shapiro-Wilk W test, quantitative values are ex-
pressed as median (interquartile range) or numbers 
with percentages. The relationship between qualita-
tive parameters was assessed by the Fisher exact test. 
The Whitney-Mann U-test was used to evaluate the 
association between the studied antibodies levels 
and various APS manifestations. A p-value < 0.05 
was considered statistically significant. Analy-
sis was performed with STATISTICA Version 9.0 
(StatSoft Inc., Tulsa, Oklahoma, USA).
Results
There were 23 (69.7%) patients with primary 
APS and 10 (30.3%) with secondary APS. At the 
enrolment visit, primary APS patients were on as-
pirin (n = 2), vitamin K antagonists (n = 3) or riva-
roxaban (n = 1). Triple positivity was observed in 
10 patients (30.3%), while there were 8 (24.2%) pa-
tients with double and 15 (45.5%) with single posi-
tivity. Characteristics of APS patients are present-
ed in Table 1. 
In patients with secondary APS, we observed 
increased levels of IgG anti-β-2GPI antibodies 
(p = 0.03) and more common positivity of LA 
(p = 0.09).
The presence of LR (n = 8, 24.2%) was related 
to a high proportion of thromboembolic manifesta-
tions of APS, including DVT, stroke and cerebral ve-
nous sinus thrombosis (4, 2, and 2 patients, respec-
tively). As shown in Table 2, LR was associated with 
increased levels of IgA aCL (p = 0.001), IgA anti-β- 
-2GPI (p = 0.002), IgG anti-β-2GPI-D1 (p = 0.005) 
and IgG anti-β-2GPI (p = 0.03) antibodies.
Occurrence of HVD (n = 9, 27.3%) was main-
ly related to DVT (6 patients) and was associat-
ed with elevated levels of IgG anti-β-2GPI-D1 
(p = 0.01), IgG anti-β-2GPI (p = 0.002) and IgG 
aCL (p = 0.01) antibodies. The association of HVD 
with increased levels of IgA aCL and IgA anti-β- 
-2GPI tended to be significant (p = 0.07).
Thrombocytopenia (n = 6, 18.2%) showed no 
associations with various types of antiphospholip-
id antibodies (Table 2).
No association between non-criteria APS mani-
festations and inherited thrombophilia, medications 
or thromboembolism were observed. In relation to 
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Discussion
A novel finding of this study is that increased 
IgG anti-β-2GPI-D1 antibodies were associated 
with the occurrence of LR and HVD in APS.
In contrast to the previous studies [3, 9, 10], 
we did not observe any relationships between in-
creased IgA aCL and anti-β-2GPI antibodies and 
thrombocytopenia. In turn, the association of 
HVD with increased levels of IgA aCL and IgA 
anti-β-2GPI approaching only borderline signifi-
cance. However, since there were 2 patients with 
HVD and 1 with thrombocytopenia with increased 
IgA aCL and anti-β-2GPI antibodies, we cannot 
exclude that in a larger patient group such associa-
tion can be found.
LR related to poorly defined vascular abnor-
malities can be a strong marker of thrombosis in 
APS [15]. We observed specific associations be-
tween LR and increased levels of 3 types of an-
tibodies, i.e. IgA aCL, IgA anti-β-2GPI and IgG 
anti-β-2GPI-D1 antibodies, which might indicate 
that these antibodies unfavorably affect vascular 
reactivity.
Interestingly, the presence of IgG anti-β- 
-2GPI-D1 antibodies was associated with HVD, 
which has been shown to have a link to thrombot-
ic processes on valves with autoimmune valvulitis, 
being a risk factor for stroke [1]. It might be specu-
lated that these antibodies displaying an uncertain 
pathogenic role may be implicated in the develop-
ment of this particular manifestation of APS.
In conclusion, our study is the first to show that 
increased IgG anti-β-2GPI-D1 antibodies are associ-
ated with LR and HVD in APS patients. Comparing 
the three variables: levels of studied antibodies, rare 
symptoms and clinical manifestations measurement 
of both IgA and IgG anti-β-2GPI-D1 antibodies may 
be helpful in diagnosing patients with symptoms 
suggestive of APS, especially when standard IgG and 
IgM of antiphospholipid antibodies were negative.
The limitation of the study was the small sam-
ple size. Further confirmation of our findings in 
larger cohorts is needed.
References
 [1] de Laat B, Mertens K, de Groot PG: Mechanisms of disease: antiphospholipid antibodies – from clinical associa-
tion to pathologic mechanism. Nat Clin Pract Rheumatol 2008, 4, 192–199.
 [2] Jeleniewicz R, Majdan M, Targońska-Stępniak B, Dryglewska M: Prevalence of antiphospholipid antibodies in 
rheumatoid arthritis patients and relationship with disease activity. Pol Arch Med Wewn 2012, 122, 480–486.
 [3] Lakos G, Kiss E, Regëczy N, Tarján P, Soltész P, Zeher M, Bodolay E, Szakony S, Sipka S, Szegedi G: Isotype 
distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. 
Clin Exp Immunol 1999, 117, 574–579.
 [4] Marchetti T, Cohen M, Gris JC, de Moerloose P: Diagnosis and management of obstetrical antiphospholipid 
syndrome: where do we stand? Pol Arch Med Wewn 2013, 123, 713–720.
 [5] Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, Rovensky J, Chapman J, Shoenfeld Y: Close asso-
ciation between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. 
Ann Rheum Dis 2005, 64, 1490–1493.
 [6] de Groot PG, Urbanus RT: The future of antiphospholipid antibody testing. Semin Thromb Hemost 2013, 38, 
412–420.
 [7] Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, 
Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA: International consensus state-
ment on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 
2006, 4, 295–306.
 [8] Andreoli L, Fredi M, Nalli C, Piantoni S, Reggia R, Dall’Ara F, Tincani A: Clinical Significance of IgA Anti-
Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies. Curr Rheumatol Rep 2013, 15, 343. doi: 10.1007/s11926-
013-0343-1.
 [9] Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, Mathieu A, Smolen J, de Ramon Garrido E, 
Fernandez-Nebro A, Jedryka-Goral A, Papasteriades C, Morozzi G, Bellisai F, De Pitá O, Marcolongo R: 
Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythe-
matosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand 
J Rheumatol 1999, 28, 344–351.
[10] Samarkos M, Davies KA, Gordon C, Loizou S: Clinical significance of IgA anticardiolipin and anti-β2-GPI anti-
bodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 
2006, 25, 199–204.
[11] Mahler M, Norman GL, Meroni PL, Khamashta M: Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promis-
ing candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12, 313–317.
[12] de Laat B, Derksen RH, Urbanus RT, de Groot PG: IgG antibodies that recognize epitope Gly40-Arg43 in domain I of 
beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005, 105, 1540–1545.
[13] de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffatti A, Rozman B, Kveder T, 
de Moerloose P, Boehlen F, Rand J, Ulcova-Gallova Z, Mertens K, de Groot PG: The association between cir-
culating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. 
J Thromb Haemost 2009, 7, 1767–1773.
APS and Heart Valve Disease 733
[14] Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG: Update of the guidelines for lupus 
anticoagulant detection. J Thromb Haemost 2009, 7, 1737–1740.
[15] Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, Blank M, Shoenfeld Y: Livedo reticularis is 
a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005, 23, 
499–504.
Address for correspondence: 
Marek Cieśla




Tel.: +48 126 14 31 45
E-mail: marek.ciesla@szpitaljp2.krakow.pl
Conflict of interest: None declared
Received: 14.03.2014
Revised: 6.05.2014
Accepted: 4.09.2014
